CNTNAP1 and Guillain-Barre syndrome: Antibodies binding Caspr1 were initially described in 2016 by Doppler and colleagues in two patients presenting severe neuropathic pain and a subacute onset, with a motor-dominant neuropathy resembling CIDP in one patient, while the other presented with a GBS-like phenotype [4].